This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Winners & Losers: King Pharma

Health stocks were mixed on relatively light news Monday, with one regulatory-inspired exception.

Big pharma stocks were both up and down -- but not by much -- pushing the Amex pharmaceutical index down about 0.59, or 0.2%, at 317.17. Component King Pharma (kg) continued a second trading day of rebounding from its earnings damage last week. The stock added 36 cents, or 3.4%, to $11.07.

On the biotech side, the Amex and Nasdaq biotechnology indices gained 1.1% and 0.9%.

A component of the Nasdaq index, Cardiome Pharma (CRME - Get Report), was creamed after the company announced receipt of an "approvable" letter for the intravenous version of its Vernakalant, an experimental drug for irregular heart rhythm.

The company said it could take several months to respond to the letter, in which the FDA asked for safety data from ongoing and completed trials. Regulators could require an additional trial, although Cardiome said it is optimistic that won't be the case. The stock was falling $2.55, or 21.3%, to $9.40.

Elsewhere, Enzon Pharmaceuticals (ENZN - Get Report) said it is exploring strategic alternatives for its specialty pharmaceutical business. The company said it might sell the entire business or one or more of its products, and its manufacturing facility in Indiana.

Enzon said it has received confidential interest in all or parts of the specialty pharmaceutical business, and is evaluating the sale process. It previously announced it would spin off its biotech business. Shares were up 4 cents to $8.80.

In earnings, Obagi Medical (OMPI) edged past Street expectations for its recent quarter but scaled back guidance. The company said it earned 20 cents a share on revenue of $27.8 million, while analysts polled by Thomson Reuters had expected 19 cents a share on $27.2 million.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CRME $8.36 0.00%
ENZN $1.02 0.00%
HALO $13.93 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs